# FORT-1 (NCT03410693)

> Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03410693
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Carcinoma, Transitional Cell
- Interventions: Rogaratinib (BAY1163877); Chemotherapy
- Enrollment: 175
- Primary outcome: Objective Response Rate (ORR) - Central Assessment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=fort-1-nct03410693